Abstract 1802
Background
Targeting programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has failed to provide durable clinical benefit for a majority of patients with solid carcinomas. Recent preclinical and clinical data suggests that addition of the IL-15 superagonist N-803 improves response rates to anti-PD-1 or anti-PD-L1 therapy. Thus, we hypothesized that N-809, a novel bifunctional agent comprised of N-803 fused to two single chain anti-PD-L1 variable region domains, would promote potent anti-tumor efficacy and immune activation in murine models of solid carcinomas.
Methods
The functionality of the N-809 components was examined in vitro. Anti-tumor efficacy of N-809 versus a clinically relevant dose of N-803 + anti-PD-L1 was assessed using murine MC38 colon and 4T1 triple negative breast tumor models. The immune-mediated mechanism of N-809 was examined in spleen and tumor using comprehensive flow-based analyses and functional assays. Serum cytokine levels were also measured. Finally, effects on tumor gene expression were examined using Nanostring. Nant biosciences provided N-809 as per Cooperative Research and Development Agreement with NCI.
Results
In vitrostudies confirmed that both components of N-809 were functional. N-809 drastically reduced MC38 tumor burden leading to increased survival and significantly reduced spontaneous lung metastasis of 4T1 tumors. In both tumor models, N-809 had improved efficacy versus a clinically relevant dose of N-803 + anti-PD-L1. In the MC38 model, N-809 increased serum levels of IFNg, TNFa, and IL-10. Depletion studies revealed that CD8+T and NK cells are required for the anti-tumor efficacy of N-809. The immune analysis showed enhanced CD8+ T and NK cell tumor infiltration, activation, and function. To determine the mechanism of the increased CD8 and NK cell infiltration, analyses were performed to examine tumor chemokines and inhibition of immune cell migration. Gene analysis revealed changes in chemokines, chemokine receptors, and immune response genes.
Conclusions
N-809 has anti-tumor efficacy in two murine carcinoma model mediated by increasing the number, activation, and function of CD8+ T cells and NK cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Funding
Nant Bioscience.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract